Ravishankar R, Samuels L E, Kaufman M S, Samuels F L, Thomas M P, Galindo L, Morris R J, Brockman S K
Department of Cardiothoracic Surgery, Allegheny University Hospitals, Hahnemann Division, Philadelphia, Pennsylvania 19102-1192, USA.
Am J Med Sci. 1998 Dec;316(6):390-2. doi: 10.1097/00000441-199812000-00006.
Amiodarone is a benzofuran derivative with a chemical structure similar to thyroxine. Originally introduced to treat angina pectoris, amiodarone was found to have antiarrhythmic properties, and in 1985, was approved in the United States for treatment of life-threatening ventricular arrhythmias. It is now used for various ventricular and supraventricular arrhythmias refractory to conventional first-line medications, and as a result, side effects have been observed with increased frequency. The most severe and potentially life-threatening of these side effects is the development of pulmonary toxicity. Typically, amiodarone pulmonary toxicity (APT) is manifested by acute pneumonitis and chronic fibrosis. Amiodarone-associated hemoptysis (AAH) is a rare occurrence. The authors describe a case of AAH successfully treated with cessation of drug and steroid therapy.
胺碘酮是一种苯并呋喃衍生物，其化学结构与甲状腺素相似。胺碘酮最初用于治疗心绞痛，后来发现它具有抗心律失常特性，并于1985年在美国被批准用于治疗危及生命的室性心律失常。它现在用于治疗对传统一线药物难治的各种室性和室上性心律失常，因此，副作用的出现频率有所增加。这些副作用中最严重且可能危及生命的是肺毒性的发生。通常，胺碘酮肺毒性（APT）表现为急性肺炎和慢性纤维化。胺碘酮相关性咯血（AAH）较为罕见。作者描述了一例通过停药和类固醇治疗成功治愈的AAH病例。
